NOVEL HIV-1 MICROBICIDES

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。前言：我们的目的是确定脂质体剂型的短干扰RNA局部滴注后是否能够被体内的宫颈阴道粘膜吸收。方法：动物月经周期与黄体酮同步。两周后，我们将针对CCR5的siRNA与脂质体复合。在给药后以不同的时间间隔评估宫颈阴道组织。我们现在正在用免疫组化和聚合酶链式反应来评估CCR5的表达。基线样本将与治疗后获得的样本进行比较。通过这种方式，我们将确定siRNA是否可以进一步开发为一种能够防止H。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Introduction: Our aim was to determine whether liposomal formulations of short interfering RNA are able to be absorbed by cervicovaginal mucosa in vivo after their local instillation. Methods: The menstrual cycle of the animals were synchronized with progesterone. Two weeks later, we complexed siRNA targeting CCR5 with liposomes. Cervicovaginal tissue was evaluated at variable intervals after administration. We are now assessing CCR5 expression by IHC and PCR. Baseline samples will be compared with those obtained after treatment. In this manner, we will determine whether siRNA can be further developed as a microbicidal drug capable of preventing the mucosal transmission of H